B+
Bull case
20%
Probability
Target price
$1.20
-71.6% vs current
TOI
Oncology InstituteCNasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
50%
Probability
Target price
$0.36
-91.5% vs current
B-
Bear case
30%
Probability
Target price
$0.12
-97.2% vs current
AI sentiment snapshot
Latest data as of 2025-11-17
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
0.0
Score
AI commentary
Market response is mixed: the NovaBio collaboration produced positive headlines and short-term optimism around OI-201, but SEC filings flag material financing and runway risks that limit conviction [#8-K-2025-11-14][#10-Q-2025-08-12]. Analysts emphasize upside if milestones materialize but highlight high dilution risk and binary clinical outcomes as dominant themes [#S-1A-2025-05-20].
RankAlpha Sentiment AI - 2025-11-17
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
-eventCash runway / going-concern execution riskHigh impact
Quarterly filing flagged a going-concern risk and limited cash runway; failure to secure partner payments or capital would likely cause sharp downside or operational disruption [#10-Q-2025-08-12].
-catalystRegistered offering / dilution risk (S-1/A)High impact
Amended S-1 filed for a proposed equity offering (up to 10,000,000 shares); a priced offering or ATM could dilute holders and pressure the share price [#S-1A-2025-05-20].
-catalystNovaBio collaboration and potential milestone paymentsHigh impact
Company announced collaboration to advance lead immunotherapy OI-201 into Phase 2 with $15.0M upfront and up to $85.0M in milestones; future milestone receipts would materially de-risk runway and could drive large upside [#8-K-2025-11-14][#PR-2025-11-14].
Recommendation
N/A
No formal recommendation provided.
As of 2025-11-17 • Updated nightlySource: Internal modelMethodology